| Year |
Citation |
Score |
| 2022 |
Coupet CA, Dubois C, Evlachev A, Kehrer N, Baldazza M, Hofman S, Vierboom M, Martin P, Inchauspe G. Intravenous injection of a novel viral immunotherapy encoding human interleukin-7 in nonhuman primates is safe and increases absolute lymphocyte count. Human Vaccines & Immunotherapeutics. 2133914. PMID 36315906 DOI: 10.1080/21645515.2022.2133914 |
0.695 |
|
| 2022 |
Crausaz M, Monneret G, Conti F, Lukaszewicz AC, Marchand JB, Martin P, Inchauspé G, Venet F. A novel virotherapy encoding human interleukin-7 improves T lymphocyte functions in immunosuppressed patients with septic shock and critically ill COVID-19. Frontiers in Immunology. 13: 939899. PMID 36045686 DOI: 10.3389/fimmu.2022.939899 |
0.702 |
|
| 2022 |
Lélu K, Dubois C, Evlachev A, Crausaz M, Baldazza M, Kehrer N, Brandely R, Schlesinger Y, Silvestre N, Marchand JB, Bastien B, Leung-Theung-Long S, Unsinger J, Martin P, Inchauspé G. Viral Delivery of IL-7 Is a Potent Immunotherapy Stimulating Innate and Adaptive Immunity and Confers Survival in Sepsis Models. Journal of Immunology (Baltimore, Md. : 1950). PMID 35667841 DOI: 10.4049/jimmunol.2101145 |
0.702 |
|
| 2019 |
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, et al. Safety and Immunogenicity of the Therapeutic Vaccine TG1050 in Chronic Hepatitis B Patients: A Phase 1b Placebo-Controlled Trial. Human Vaccines & Immunotherapeutics. PMID 31373537 DOI: 10.1080/21645515.2019.1651141 |
0.753 |
|
| 2018 |
Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model. Human Vaccines & Immunotherapeutics. 0. PMID 29388874 DOI: 10.1080/21645515.2018.1433970 |
0.748 |
|
| 2015 |
Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML. Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes. Vaccine. 33: 4548-53. PMID 26209840 DOI: 10.1016/J.Vaccine.2015.07.020 |
0.774 |
|
| 2015 |
Lélu K, Evlachev A, Kratzer R, Dion S, Mancini-Bourgine M, Godon O, Schmitt D, Dubois C, Mériter J-, Schlesinger Y, Marchand J-, Geist M, Brandely R, Findeli A, Menguy T, ... ... Martin P, et al. O031 : TG1050, a novel immunotherapeutic to treat chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30039-8 |
0.465 |
|
| 2015 |
Lélu K, Evlachev A, Kratzer R, Godon O, Mancini-Bourgine M, Dion S, Schmitt D, Dubois C, Meritet JF, Schlesinger Y, Marchand JB, Geist M, Brandely R, Findeli A, Zhu R, ... ... Martin P, et al. TG1050, a novel immunotherapeutic for the treatment of chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models Journal of Clinical Virology. 69: 227. DOI: 10.1016/J.Jcv.2015.06.020 |
0.361 |
|
| 2014 |
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut. PMID 25429051 DOI: 10.1136/Gutjnl-2014-308041 |
0.743 |
|
| 2014 |
Boukhebza H, Dubois C, Koerper V, Evlachev A, Schlesinger Y, Menguy T, Silvestre N, Riedl P, Inchauspé G, Martin P. Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models. Vaccine. 32: 3256-63. PMID 24726690 DOI: 10.1016/J.Vaccine.2014.03.089 |
0.785 |
|
| 2013 |
Boukhebza H, Dubois C, Schlesinger Y, Koerper V, Brandely R, Geist M, Menguy T, Silvestre N, Schirmbeck R, Inchauspé G, Martin P. 391 PRE-CLINICAL PROOF-OF-CONCEPT STUDIES EXPLORING SCHEDULES OF ADMINISTRATION OF AN ADENOVIRUS- BASED HBV IMMUNOTHERAPEUTIC SHOW WIDE POTENTIAL FOR INDUCTION OF ROBUST AND LONG-LASTING T-CELL RESPONSES Journal of Hepatology. 58: S161. DOI: 10.1016/S0168-8278(13)60393-1 |
0.741 |
|
| 2013 |
Martin P, Dubois C, Jacquier E, Evlachev A, Boukhebza H, Dion S, Mancini-Bourgine M, Godon O, Findeli A, Schlesinger Y, Brandely R, Marchand J, Menguy T, Silvestre N, Schirmbeck R, et al. 130 A MULTIVALENT ADENOVIRUS-BASED IMMUNOTHERAPEUTIC FOR TREATMENT OF CHRONIC HEPATITIS B INDUCES BROAD, ROBUST AND POLYFUNCTIONAL T CELLS IN NAIVE AND HBV TOLERANT MICE Journal of Hepatology. 58: S57-S58. DOI: 10.1016/S0168-8278(13)60132-4 |
0.787 |
|
| 2012 |
Martin P, Evlachev A, Olivier D, Beny C, Dubois C, Findeli A, Schlesinger Y, Ledoux C, Brandely R, Menguy T, Silvestre N, Fournillier A, Bonnefoy J-, Inchauspé G. 449 Towards The Development Of A Therapeutic Vaccine To Treat Chronic Hbv Infection: Ad5-Based Vaccines Encoding Multiple Hbv Antigens Induce Strong T-Cell Responses In Pre-Clinical Models Journal of Hepatology. 56. DOI: 10.1016/S0168-8278(12)60462-0 |
0.502 |
|
| 2009 |
Inchauspe G, Bach G, Martin P, Bonnefoy JY. Vaccination against hepatitis B and C: towards therapeutic application. International Reviews of Immunology. 28: 7-19. PMID 19241251 DOI: 10.1080/08830180802488436 |
0.757 |
|
| 2008 |
Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspé G, Fournillier A. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine. 26: 2471-81. PMID 18423948 DOI: 10.1016/J.Vaccine.2008.03.028 |
0.51 |
|
| 2007 |
Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul JM, Barry R, Inchauspé G. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine. 25: 7339-53. PMID 17875349 DOI: 10.1016/J.Vaccine.2007.08.020 |
0.51 |
|
| 2006 |
Martin P, Parroche P, Pajot A, Chatel L, Barreto C, Touat L, Dubois V, Rohrlich PS, Bain C, Trépo C, Negro F, Inchauspé G, Fournillier A. Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein. Microbes and Infection / Institut Pasteur. 8: 2432-41. PMID 16859951 DOI: 10.1016/J.Micinf.2006.05.006 |
0.775 |
|
| 2006 |
Fournillier A, Dupeyrot P, Martin P, Parroche P, Pajot A, Chatel L, Fatmi A, Gerossier E, Bain C, Lone YC, Trépo C, Inchauspé G. Primary and memory T cell responses induced by hepatitis C virus multiepitope long peptides. Vaccine. 24: 3153-64. PMID 16481078 DOI: 10.1016/J.Vaccine.2006.01.039 |
0.727 |
|
| 2006 |
Inchauspe GJ, Fournillier A, Gerossier E, Evlachev A, Martin P, Chafel L, Schmidt D, Silvestre N. O.013 Potent T-cell immunity induced by a hepatitis C virus candidate vaccine based on a non-replicative poxvirus Journal of Clinical Virology. 36. DOI: 10.1016/S1386-6532(06)80022-3 |
0.526 |
|
| 2006 |
Martin P, Inchauspé G. Hepatitis C vaccines Drug Discovery Today: Therapeutic Strategies. 3: 203-209. DOI: 10.1016/J.Ddstr.2006.05.004 |
0.718 |
|
| 2004 |
Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trépo C, Bain C, Lone YC, Inchauspé G, Fournillier A. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. Journal of Medical Virology. 74: 397-405. PMID 15368525 DOI: 10.1002/Jmv.20189 |
0.75 |
|
| 2003 |
Seignères B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trépo C, Zoulim F. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrobial Agents and Chemotherapy. 47: 1842-52. PMID 12760857 DOI: 10.1128/Aac.47.6.1842-1852.2003 |
0.449 |
|
| 2002 |
Seignères B, Pichoud C, Martin P, Furman P, Trépo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology (Baltimore, Md.). 36: 710-22. PMID 12198665 DOI: 10.1053/Jhep.2002.35070 |
0.399 |
|
| Show low-probability matches. |